Novel tetrahydroisoquinolines as DHFR and CDK2 inhibitors: synthesis, characterization, anticancer activity and antioxidant properties

被引:5
作者
Sayed, Eman M. [1 ]
Bakhite, Etify A. [2 ]
Hassanien, Reda [1 ]
Farhan, Nasser [1 ]
Aly, Hanan F. [3 ]
Morsy, Salma G. [4 ]
Hassan, Nivin A. [5 ]
机构
[1] New Valley Univ, Fac Sci, Dept Chem, El Kharja 72511, Egypt
[2] Assiut Univ, Fac Sci, Dept Chem, Assiut 71516, Egypt
[3] Natl Res Ctr, Dept Therapeut Chem, El Behooth St, Cairo 12622, Egypt
[4] Assiut Univ, South Egypt Canc Inst, Dept Canc Biol, Canc Immunol & Virol Unit, Assiut, Egypt
[5] Assiut Univ, South Egypt Canc Inst, Dept Canc Biol, Pharmacol & Expt Oncol Unit, Assiut, Egypt
关键词
Anticancers; Apoptosis; Cell cycle arrest; CDK2; inhibitor; DHFR inhibitor; Antioxidants; Tetrahydroisoquinolines; Tetrahydrothieno[2,3-c]isoquinolines; CYCLIN-DEPENDENT KINASES; BIOLOGICAL EVALUATION; ISOQUINOLINE; DERIVATIVES; PROLIFERATION;
D O I
10.1186/s13065-024-01139-w
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
In this study, we synthesized new 5,6,7,8-tetrahydroisoquinolines and 6,7,8,9-tetrahydrothieno[2,3-c]isoquinolines based on 4-(N,N-dimethylamino)phenyl moiety as expected anticancer and/or antioxidant agents. The structure of all synthesized compounds were confirmed by spectral date (FT-IR, 1H NMR, 13C NMR) and elemental analysis. We evaluated the anticancer activity of these compounds toward two cell lines: A459 cell line (lung cancer cells) and MCF7 cell line (breast cancer cells). All tested compounds showed moderate to strong anti-cancer activity towards the two cell lines. Compound 7e exhibited the most potent cytotoxic activity against A549 cell line (IC50: 0.155 mu M) while compound 8d showed the most potent one against MCF7 cell line (IC50: 0.170 mu M) in comparison with doxorubicin. In addition, we examined the effect of compounds 7e and 8d regarding the growth of A549 and MCF7 cell lines, employing flow cytometry and Annexin V-FITC apoptotic assay. Our results showed that compound 7e caused cell cycle arrest at the G2/M phase with a 79-fold increase in apoptosis of A459 cell line. Moreover, compound 8d caused cell cycle arrest at the S phase with a 69-fold increase in apoptosis of MCF7 cell line. Furthermore, we studied the activity of these compounds as enzyme inhibitors against several enzymes. Our findings by docking and experimental studies that compound 7e is a potent CDK2 inhibitor with IC50 of 0.149 mu M, compared to the Roscovitine control drug with IC50 of 0.380 mu M. We also found that compound 8d is a significant DHFR inhibitor with an IC50 of 0.199 mu M, compared to Methotrexate control drug with IC50 of 0.131 mu M. Evaluation of the antioxidant properties of ten compounds was also studied in comparison with Vitamin C. Compounds 1, 3, 6, 7c and 8e have higher antioxidant activity than Vitamin C which mean that these compounds can used as potent antioxidant drugs.
引用
收藏
页数:19
相关论文
共 55 条
  • [1] Ahmed KO., 2019, Phytochem Lett, V29, P11
  • [2] Novel [(N-alkyl-3-indolylmethylene)hydrazono]oxindoles arrest cell cycle and induce cell apoptosis by inhibiting CDK2 and Bcl-2: synthesis, biological evaluation andin silicostudies
    Al-Warhi, Tarfah
    Abo-Ashour, Mahmoud F.
    Almahli, Hadia
    Alotaibi, Ohoud J.
    Al-Sanea, Mohammad M.
    Al-Ansary, Ghada H.
    Ahmed, Hanaa Y.
    Elaasser, Mahmoud M.
    Eldehna, Wagdy M.
    Abdel-Aziz, Hatem A.
    [J]. JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2020, 35 (01) : 1300 - 1309
  • [3] Alagumuthu M., 2015, International Journal of Pharmaceutical Sciences, V7, P200
  • [4] The history and future of targeting cyclin-dependent kinases in cancer therapy
    Asghar, Uzma
    Witkiewicz, Agnieszka K.
    Turner, Nicholas C.
    Knudsen, Erik S.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2015, 14 (02) : 130 - 146
  • [5] Brahmayya M., 2012, J Appl Pharm Sci, V2, P041
  • [6] Targeting cyclin-dependent kinases in anti-neoplastic therapy
    Bruyere, Celine
    Meijer, Laurent
    [J]. CURRENT OPINION IN CELL BIOLOGY, 2013, 25 (06) : 772 - 779
  • [7] Cyclin-Dependent Kinase (CDK) Inhibitors: Structure Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines
    Coxon, Christopher R.
    Anscombe, Elizabeth
    Harnor, Suzannah J.
    Martin, Mathew P.
    Carbain, Benoit
    Golding, Bernard T.
    Hardcastle, Ian R.
    Harlow, Lisa K.
    Korolchuk, Svitlana
    Matheson, Christopher J.
    Newel, David R.
    Noble, Martin E. M.
    Sivaprakasam, Mangaleswaran
    Tudhope, Susan J.
    Turner, David M.
    Wang, Lan Z.
    Wedge, Stephen R.
    Wong, Christopher
    Griffin, Roger J.
    Endicott, Jane A.
    Cano, Celine
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2017, 60 (05) : 1746 - 1767
  • [8] Synthesis of new indeno[1,2-c]isoquinolines:: Cytotoxic non-camptothecin topoisomerase I inhibitors
    Cushman, M
    Jayaraman, M
    Vroman, JA
    Fukunaga, AK
    Fox, BM
    Kohlhagen, G
    Strumberg, D
    Pommier, Y
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (20) : 3688 - 3698
  • [9] Novel Tetrahydro-[1,2,4]triazolo[3,4-a]isoquinoline Chalcones Suppress Breast Carcinoma through Cell Cycle Arrests and Apoptosis
    Darwish, Mahmoud I. M.
    Moustafa, Ahmed M.
    Youssef, Asmaa M.
    Mansour, Mohamed
    Yousef, Ahmed I.
    El Omri, Abdelfatteh
    Shawki, Hossam H.
    Mohamed, Magda F.
    Hassaneen, Hamdi M.
    Abdelhamid, Ismail A.
    Oishi, Hisashi
    [J]. MOLECULES, 2023, 28 (08):
  • [10] PYRROLO[4,3,2-DE]ISOQUINOLINES WITH CENTRAL NERVOUS-SYSTEM AND ANTIHYPERTENSIVE ACTIVITIES
    DEMERSON, CA
    PHILIPP, AH
    HUMBER, LG
    KRAML, MJ
    CHAREST, MP
    TOM, H
    VAVRA, I
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1974, 17 (11) : 1140 - 1145